LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10A | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 1694 | 9580 | 11103 | 0.8627 | 0.8938 |
MCF 10A | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 1694 | 7094 | 11103 | 0.6390 | 0.6953 |
MCF 10A | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 1694 | 5375 | 11103 | 0.4842 | 0.5302 |
MCF 10A | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 1694 | 2858 | 11103 | 0.2574 | 0.2126 |
MCF 10A | Dovitinib | 10 | uM | LJP5 | 72 | hr | 1694 | 1920 | 11103 | 0.1730 | 0.0472 |
MCF 10A | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 1694 | 11282 | 11103 | 1.0161 | 1.0118 |
MCF 10A | GSK 690693 | 0.12 | uM | LJP5 | 72 | hr | 1694 | 11154 | 11103 | 1.0046 | 1.0033 |
MCF 10A | GSK 690693 | 0.37 | uM | LJP5 | 72 | hr | 1694 | 10752 | 11103 | 0.9684 | 0.9764 |
MCF 10A | GSK 690693 | 1.11 | uM | LJP5 | 72 | hr | 1694 | 9787 | 11103 | 0.8815 | 0.9091 |
MCF 10A | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 1694 | 9870 | 11103 | 0.8890 | 0.9151 |
MCF 10A | GSK 690693 | 10 | uM | LJP5 | 72 | hr | 1694 | 10102 | 11103 | 0.9098 | 0.9314 |
MCF 10A | SNS-032 | 0.04 | uM | LJP6 | 72 | hr | 1694 | 11126 | 11217 | 0.9919 | 0.9940 |
MCF 10A | SNS-032 | 0.12 | uM | LJP6 | 72 | hr | 1694 | 1915 | 11217 | 0.1708 | 0.0460 |
MCF 10A | SNS-032 | 0.37 | uM | LJP6 | 72 | hr | 1694 | 464 | 11217 | 0.0414 | -0.3793 |
MCF 10A | SNS-032 | 1.11 | uM | LJP6 | 72 | hr | 1694 | 309 | 11217 | 0.0276 | -0.4641 |
MCF 10A | SNS-032 | 3.33 | uM | LJP6 | 72 | hr | 1694 | 308 | 11217 | 0.0275 | -0.4650 |
MCF 10A | SNS-032 | 10 | uM | LJP6 | 72 | hr | 1694 | 366 | 11217 | 0.0327 | -0.4307 |
MCF 10A | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 1694 | 1726 | 11217 | 0.1540 | 0.0062 |
MCF 10A | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 1694 | 1655 | 11217 | 0.1476 | -0.0089 |
MCF 10A | Afatinib | 0.37 | uM | LJP6 | 72 | hr | 1694 | 1703 | 11217 | 0.1519 | 0.0003 |
MCF 10A | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 1694 | 1789 | 11217 | 0.1596 | 0.0177 |
MCF 10A | Afatinib | 3.33 | uM | LJP6 | 72 | hr | 1694 | 1868 | 11217 | 0.1666 | 0.0363 |
MCF 10A | Afatinib | 10 | uM | LJP6 | 72 | hr | 1694 | 1764 | 11217 | 0.1573 | 0.0144 |
MCF 10A | GSK1904529A | 0.04 | uM | LJP6 | 72 | hr | 1694 | 7707 | 11217 | 0.6872 | 0.7429 |
MCF 10A | GSK1904529A | 0.12 | uM | LJP6 | 72 | hr | 1694 | 7248 | 11217 | 0.6462 | 0.7039 |